Last reviewed · How we verify
NCT05349045: AIPAAIAEC
Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
trial testing an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor in Esophageal Neoplasms in 300 participants. Status unknown.
5 May 2024
Quick facts
| Lead sponsor | The First Affiliated Hospital of Zhengzhou University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 5 May 2022 |
| Primary completion | 5 May 2024 |
| Estimated completion | 5 May 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor — full drug profile →
Conditions studied
- Esophageal Neoplasms — all drugs for Esophageal Neoplasms →
Sponsor
The First Affiliated Hospital of Zhengzhou University
Who can join
Eligibility, any sex, with Esophageal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis.
Ren Y, Wang R, Weng S, Xu H, et al · · 2023 · cited 87× · PMID 37563639 · DOI 10.1186/s12943-023-01831-w
Verify or expand the search:
- PubMed search for NCT05349045
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Esophageal Neoplasms
Currently open trials in the same condition.
- NCT07482566 — Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer · NA · recruiting
- NCT07272382 — Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer · NA · recruiting
- NCT06469944 — Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First · Phase 1, PHASE2 · recruiting
- NCT07035587 — Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity · recruiting
- NCT06445972 — Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) · Phase 1, PHASE2 · recruiting
Other The First Affiliated Hospital of Zhengzhou University trials
Trials by the same sponsor.
- NCT07501962 — Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate · NA · not yet recruiting
- NCT07501975 — Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality · NA · not yet recruiting
- NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
- NCT05114941 — Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome · NA · not yet recruiting
- NCT07314619 — Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combi · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05349045 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Zhengzhou University
- Last refreshed: 27 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05349045.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing